ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
ArQule signed a two-part deal with Daiichi Sankyo Nov. 10 that gives the biotech important non-dilutive funding as well as validation for its discovery platform. In exchange for broad commercialization rights to ArQule's lead compound, the Phase II oncologic ARQ 197, Daiichi will pay $75 million in upfront funding along with up to $560 million in potential milestones
You may also be interested in...
Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News
TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology
Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News
TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application